tiprankstipranks
SIGA Technologies Inc (SIGA)
NASDAQ:SIGA
US Market
Want to see SIGA full AI Analyst Report?

SIGA Technologies (SIGA) Price & Analysis

493 Followers

SIGA Stock Chart & Stats

$6.77
-$0.07(-1.11%)
At close: 4:00 PM EST
$6.77
-$0.07(-1.11%)

Bulls Say, Bears Say

Bulls Say
Strong Liquidity & No DebtA cash balance near $146M with zero debt provides multi-quarter runway and optionality. This durable strength reduces refinancing risk, funds ongoing pediatric/PEP development, underpins special dividends, and allows the company to sustain operations through lumpy procurement cycles while preserving strategic flexibility.
Positive Cash GenerationPositive operating and free cash flow on a TTM basis indicate the business can generate internal funding despite accounting losses. Sustainable cash conversion supports R&D spend, manufacturing tech transfer, and shareholder returns; however, the decline in FCF versus prior periods warrants monitoring of conversion durability.
Contract Visibility & International ExpansionAn exclusive Hikma MENA distribution agreement and confirmed near-term international deliveries ($13M Q2 order) materially broaden commercial pathways beyond U.S. stockpiles. Structural expansion into MENA and Asia-Pacific can diversify counterparty concentration and create recurring regional registration and sales opportunities over the medium term.
Bears Say
Sharp Revenue Decline & Large TTM LossA pronounced recent revenue contraction and an outsized trailing-twelve-month net loss overwhelm historical high gross margins and weaken earnings durability. Sustained declines reduce reinvestment capacity, impair return metrics, and increase sensitivity to timing of episodic government orders and any single large contract outcomes.
Concentrated, Lumpy Government DemandHeavy reliance on government procurement and stockpiling produces episodic order flows and limited predictability. This structural concentration elevates revenue volatility, complicates capacity planning and cashflow forecasting, and increases exposure to procurement timing, policy shifts, or single-buyer negotiation dynamics.
Regulatory Setback In EuropeThe CHMP recommendation to withdraw MPOXX's indication in Europe constitutes a structural regulatory headwind that can constrain European commercialization and partner economics. Resolving or mitigating the withdrawal will require regulatory work, may limit market access, and raises execution risk for international revenue diversification.

SIGA Technologies News

SIGA FAQ

What was SIGA Technologies Inc’s price range in the past 12 months?
SIGA Technologies Inc lowest stock price was $3.42 and its highest was $9.62 in the past 12 months.
    What is SIGA Technologies Inc’s market cap?
    SIGA Technologies Inc’s market cap is $253.90M.
      When is SIGA Technologies Inc’s upcoming earnings report date?
      SIGA Technologies Inc’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
        How were SIGA Technologies Inc’s earnings last quarter?
        SIGA Technologies Inc released its earnings results on May 07, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.05.
          Is SIGA Technologies Inc overvalued?
          According to Wall Street analysts SIGA Technologies Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does SIGA Technologies Inc pay dividends?
            SIGA Technologies Inc pays a Notavailable dividend of $0.6 which represents an annual dividend yield of N/A. See more information on SIGA Technologies Inc dividends here
              What is SIGA Technologies Inc’s EPS estimate?
              SIGA Technologies Inc’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does SIGA Technologies Inc have?
              SIGA Technologies Inc has 71,724,100 shares outstanding.
                What happened to SIGA Technologies Inc’s price movement after its last earnings report?
                SIGA Technologies Inc reported an EPS of -$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.48%.
                  Which hedge fund is a major shareholder of SIGA Technologies Inc?
                  Currently, no hedge funds are holding shares in SIGA
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    SIGA Technologies Stock Smart Score

                    Company Description

                    SIGA Technologies Inc

                    SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.

                    SIGA Technologies (SIGA) Earnings & Revenues

                    SIGA Earnings Call

                    Q1 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call presents a generally positive strategic and financial position driven by a strong cash balance, shareholder-friendly capital return, confirmed near-term international orders, regional commercial expansion via an exclusive Hikma agreement, and concrete pipeline progress (pediatric IND and PEP pathway). Offsetting these positives are the quarter's minimal deliveries and lumpy revenue profile, a small quarterly loss, a CHMP recommendation to withdraw the MPOXX indication in Europe, and slower progress toward a new U.S. government contract. Overall, the positives (liquidity, contracts, partnerships, and pipeline momentum) outweigh the near-term operational and regulatory headwinds.View all SIGA earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Emergent Biosolutions
                    Esperion
                    Organogenesis Holdings
                    Aquestive Therapeutics

                    Ownership Overview

                    1.75%12.31%11.30%63.37%
                    11.30% Other Institutional Investors
                    63.37% Public Companies and
                    Individual Investors
                    Popular Stocks